Taken together, our findings suggest that the HK2 inhibition/DPI/PER combination is a potential precision therapeutic approach to treatments for cancers with the HK1−HK2+ characteristic existing in a broad spectrum of cancer types, regardless of their tissues of origin. Here, PER1 is linked to cancer.